Jennifer A Pietenpol

发表

Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems*

David Siegel, David Ross, J. Pietenpol, 2003, The Journal of Biological Chemistry.

Triple-negative breast cancer: molecular subtypes and new targets for therapy.

A. Tan, J. Pietenpol, B. Lehmann, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

Funda Meric-Bernstam, Keith A Baggerly, Naoto T Ueno, 2013, Clinical Cancer Research.

Patient-derived breast tumor xenografts facilitating personalized cancer therapy

Jenny C. Chang, J. Pietenpol, B. Lehmann, 2013, Breast Cancer Research.

Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis.

Christopher E Barbieri, J. Pietenpol, C. Barbieri, 2006, Cancer research.

The DNA binding activity of p53 displays reaction-diffusion kinetics.

Peter Hinow, Christopher E Barbieri, Emmanuele DiBenedetto, 2006, Biophysical journal.

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Gordon B Mills, Carlos L Arteaga, Justin M Balko, 2014, Breast Cancer Research.

Syk: a new player in the field of breast cancer

J. Pietenpol, Z. A. Stewart, Jennifer A Pietenpol, 2000, Breast Cancer Research.

Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes

J. Pietenpol, B. Lehmann, Jennifer A Pietenpol, 2014, The Journal of pathology.

Chromatin Immunoprecipitation-Based Screen To Identify Functional Genomic Binding Sites for Sequence-Specific Transactivators

J. Pietenpol, D. Mays, K. L. Schavolt, 2005, Molecular and Cellular Biology.

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells

Yu Shyr, Fei Ye, Carlos L Arteaga, 2010, Breast Cancer Research.

Significance of p63 amplification and overexpression in lung cancer development and prognosis.

Yu Shyr, Pierre P Massion, P. Massion, 2003, Cancer research.

Prostate cancer serum biomarker discovery through proteomic analysis of alpha‐2 macroglobulin protein complexes

Dean Billheimer, David L Tabb, Amy-Joan L Ham, 2008, Proteomics. Clinical applications.

Cell-cycle dysregulation and anticancer therapy.

J. Pietenpol, M. Westfall, Z. A. Stewart, 2003, Trends in pharmacological sciences.

p63: Molecular complexity in development and cancer.

J. Pietenpol, M. Westfall, Jennifer A Pietenpol, 2004, Carcinogenesis.

Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives

Yu Shyr, Fei Ye, Y. Shyr, 2012, BMC Genomics.